Find Cedazuridine manufacturers, exporters & distributors on PharmaCompass

PharmaCompass

Synopsis

Related ProductsRelated Products

Synopsis

ACTIVE PHARMA INGREDIENTS

0

CEP/COS

CEP/COS Certifications

0

JDMF

JDMFs Filed

0

EU WC

EU WC

0

KDMF

KDMF

0

VMF

NDC API

0

Listed Suppliers

Other Suppliers

API REF. PRICE (USD/KG)

$
$ 0

MARKET PLACE

0

API

0

FDF

0INTERMEDIATES

FINISHED DOSAGE FORMULATIONS

0

Australia

Australia

0

South Africa

South Africa

0

Listed Dossiers

Listed Dossiers

FDF Dossiers

DRUG PRODUCT COMPOSITIONS

REF. STANDARDS OR IMPURITIES

0

EDQM

0

USP

0

JP

0

Others

PATENTS & EXCLUSIVITIES

0

Health Canada Patents

DIGITAL CONTENT

0

Stock Recap #PipelineProspector

0

Weekly News Recap #Phispers

GLOBAL SALES INFORMATION

US Medicaid

NA

0RELATED EXCIPIENT COMPANIES

0EXCIPIENTS BY APPLICATIONS

Chemistry

Click the arrow to open the dropdown
read-moreClick the button for full data set
Also known as: 1141397-80-9, Cedazuridine [inn], Cedazuridine [usan], 39is23q1ew, Chembl3237547, E7727
Molecular Formula
C9H14F2N2O5
Molecular Weight
268.21  g/mol
InChI Key
VUDZSIYXZUYWSC-DBRKOABJSA-N
FDA UNII
39IS23Q1EW

Cedazuridine
Cedazuridine is an orally available synthetic nucleoside analog derived from tetrahydrouridine (THU) and cytidine deaminase inhibitor (CDAi), that can potentially be used to prevent the breakdown of cytidines. Upon oral administration, cedazuridine binds to and inhibits CDA, an enzyme primarily found in the gastrointestinal (GI) tract and liver that catalyzes the deamination of cytidine and cytidine analogs. Given in combination with a cytidine, such as the antineoplastic hypomethylating agent decitabine, it specifically prevents its breakdown and increases its bioavailability and efficacy. In addition, this allows for lower doses of decitabine to be administered, which results in decreased decitabine-associated GI toxicity.
1 2D Structure

Cedazuridine

2 Identification
2.1 Computed Descriptors
2.1.1 IUPAC Name
(4R)-1-[(2R,4R,5R)-3,3-difluoro-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-4-hydroxy-1,3-diazinan-2-one
2.1.2 InChI
InChI=1S/C9H14F2N2O5/c10-9(11)6(16)4(3-14)18-7(9)13-2-1-5(15)12-8(13)17/h4-7,14-16H,1-3H2,(H,12,17)/t4-,5-,6-,7-/m1/s1
2.1.3 InChI Key
VUDZSIYXZUYWSC-DBRKOABJSA-N
2.1.4 Canonical SMILES
C1CN(C(=O)NC1O)C2C(C(C(O2)CO)O)(F)F
2.1.5 Isomeric SMILES
C1CN(C(=O)N[C@@H]1O)[C@H]2C([C@@H]([C@H](O2)CO)O)(F)F
2.2 Other Identifiers
2.2.1 UNII
39IS23Q1EW
2.3 Synonyms
2.3.1 MeSH Synonyms

1. (4r)-2'-deoxy-2',2'-difluoro-3,4,5,6-tetrahydrouridine

2.3.2 Depositor-Supplied Synonyms

1. 1141397-80-9

2. Cedazuridine [inn]

3. Cedazuridine [usan]

4. 39is23q1ew

5. Chembl3237547

6. E7727

7. Astx727 Component Cedazuridine

8. Astx-727 Component Cedazuridine

9. (4r)-2'-deoxy-2',2'-difluoro-3,4,5,6-tetrahydrouridine

10. E-7727

11. (4r)-1-[(2r,4r,5r)-3,3-difluoro-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-4-hydroxy-1,3-diazinan-2-one

12. Uridine, 2'-deoxy-2',2'-difluoro-3,4,5,6-tetrahydro-, (4r)-

13. (r)-1-((2r,4r,5r)-3,3-difluoro-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-4-hydroxytetrahydropyrimidin-2(1h)-one

14. Cedazuridine [usan:inn]

15. Unii-39is23q1ew

16. Cedazuridine [who-dd]

17. Schembl172256

18. Gtpl11101

19. Cedazuridine [orange Book]

20. Ex-a5549

21. Inqovi Component Cedazuridine

22. Bdbm50007029

23. Who 10741

24. Astx727 (cedazuridine + Decitabine)

25. At22227

26. Cedazuridine Component Of Inqovi

27. Compound 7a [pmid: 24520856]

28. A937507

29. (4r)-4-hydroxy-1-(2,2-difluoro-2-deoxy-beta-d-ribofuranosyl)-3,4,5,6-tetrahydropyrimidine-2(1h)-one

2.4 Create Date
2009-05-25
3 Chemical and Physical Properties
Molecular Weight 268.21 g/mol
Molecular Formula C9H14F2N2O5
XLogP3-1.1
Hydrogen Bond Donor Count4
Hydrogen Bond Acceptor Count7
Rotatable Bond Count2
Exact Mass268.08707788 g/mol
Monoisotopic Mass268.08707788 g/mol
Topological Polar Surface Area102 Ų
Heavy Atom Count18
Formal Charge0
Complexity343
Isotope Atom Count0
Defined Atom Stereocenter Count4
Undefined Atom Stereocenter Count0
Defined Bond Stereocenter Count0
Undefined Bond Stereocenter Count0
Covalently Bonded Unit Count1
4 Drug and Medication Information
4.1 Drug Indication

Cedazuridine, in combination with decitabine, is indicated for the treatment of myelodysplastic syndromes (MDS), including MDS with refractory anemia, MDS with refractory anemia and ringed sideroblasts, MDS with refractory anemia and excess blasts, MDS scoring intermediate-1, intermediate-2, or high-risk on the International Prognostic Scoring System (IPSS), and chronic myelomonocytic leukemia (CMML).


5 Pharmacology and Biochemistry
5.1 Pharmacology

Cedazuridine is a cytidine deaminase inhibitor that is co-administered with hypomethylating agents such as [decitabine] in order to increase their oral bioavailability. In combination with hypomethylating agents, cedazuridine may cause myelosuppression and embryo-fetal toxicity and should be administered with appropriate monitoring.


5.2 Absorption, Distribution and Excretion

Absorption

Cedazuridine (100 mg) taken orally with [decitabine] (35 mg) once daily for five days resulted in a day 1 AUC and steady-state AUC (coefficient of variation) of 103 (55%) and 178 (53%) ng\*hr/mL for [decitabine] and 2950 (49%) and 3291 (45%) ng\*hr/mL for cedazuridine, respectively. Overall, the 5-day cumulative AUC for [decitabine] was 851 (50%). Similarly, the Cmax for [decitabine] and cedazuridine was 145 (55%) and 371 (52%) ng/mL, respectively. The median Tmax for [decitabine] was 1 hr (range 0.3 to 3.0 hrs) and for cedazuridine was 3 hrs (range 1.5 to 6.1 hrs). The bioavailability of [decitabine], as assessed by comparing the AUC of oral [decitabine] co-administered with cedazuridine to intravenous [decitabine] alone, was 60% on day 1 (90% CI of 55-65%). The corresponding values on day 5 and considering the cumulative day 5 dose were 106% (90% CI: 98, 114) and 99% (90% CI: 93, 106). Hence, the oral bioavailability of [decitabine] approaches 100% over the 5-day treatment cycle.


Route of Elimination

Roughly 46% of cedazuridine is found in urine, 21% of which is unchanged, and 51% is found in feces, 27% of which is unchanged.


Volume of Distribution

The apparent volume of distribution (and coefficient of variation) of [decitabine] and cedazuridine at steady state was 417 (54%) and 296 (51%), respectively.


Clearance

Cedazuridine has an apparent steady-state clearance of 30.3 L/hours, with a coefficient of variation of 46%.


5.3 Metabolism/Metabolites

The metabolism of cedazuridine is not well-established. Cedazuridine is known to be converted to an epimer that is roughly 10-fold less effective in inhibiting cytidine deaminase and is subsequently degraded through unknown pathways.


5.4 Biological Half-Life

Cedazuridine has a steady-state half-life of 6.7 hours, with a coefficient of variation of 19%.


5.5 Mechanism of Action

Myelodysplastic syndromes (MDS) represent a heterogeneous group of hematopoietic neoplasms arising from a variety of underlying mutations that manifest in peripheral cytopenias and may eventually progress to secondary acute myeloid leukemia (sAML). There are over 45 genes commonly mutated in MDS patients, including those involved in DNA methylation and repair, histone modification, RNA splicing, transcription, signal transduction, and cellular adhesion. It is hypothesized that initial clonal founder mutations give rise to progressive acquisition of secondary mutations and facilitate disease progression to sAML. Hypomethylating agents such as [decitabine] are metabolized into triphosphate derivatives that are subsequently incorporated into DNA. Once incorporated, these agents inhibit the activity of DNA methylases such as DNMT1, leading to progressive DNA hypomethylation and eventual activation of tumour suppression genes and apoptotic pathways. However, hypomethylating agents given orally are vulnerable to first-pass metabolism by cytidine deaminase, and hence typically have to be administered through intramuscular or intravenous routes. Co-administration with cedazuridine, which is an efficient inhibitor of cytidine deaminase, drastically increases the oral bioavailability of [decitabine], allowing for combination oral therapy.


Digital Content read-more

Create Content with PharmaCompass, ask us

DATA COMPILATION #PharmaFlow

read-more
read-more

NEWS #PharmaBuzz

read-more
read-more

Global Sales Information

Do you need Business Intel? Ask us

Patents & EXCLUSIVITIES

Check the patents & exclusivity for this product

ABOUT THIS PAGE

Cedazuridine Manufacturers

A Cedazuridine manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Cedazuridine, including repackagers and relabelers. The FDA regulates Cedazuridine manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Cedazuridine API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.

Cedazuridine Suppliers

A Cedazuridine supplier is an individual or a company that provides Cedazuridine active pharmaceutical ingredient (API) or Cedazuridine finished formulations upon request. The Cedazuridine suppliers may include Cedazuridine API manufacturers, exporters, distributors and traders.

click here to find a list of Cedazuridine suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.

Cedazuridine USDMF

A Cedazuridine DMF (Drug Master File) is a document detailing the whole manufacturing process of Cedazuridine active pharmaceutical ingredient (API) in detail. Different forms of Cedazuridine DMFs exist exist since differing nations have different regulations, such as Cedazuridine USDMF, ASMF (EDMF), JDMF, CDMF, etc.

A Cedazuridine DMF submitted to regulatory agencies in the US is known as a USDMF. Cedazuridine USDMF includes data on Cedazuridine's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Cedazuridine USDMF is kept confidential to protect the manufacturer’s intellectual property.

click here to find a list of Cedazuridine suppliers with USDMF on PharmaCompass.

Cedazuridine NDC

National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Cedazuridine as an active pharmaceutical ingredient (API).

Finished drug products

The FDA updates the NDC directory daily. The NDC numbers for Cedazuridine API and other APIs are published in this directory by the FDA.

Unfinished drugs

The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.

Pharmaceutical companies that manufacture Cedazuridine as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.

Compounded drug products

The NDC directory also contains data on finished compounded human drug products that contain Cedazuridine and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Cedazuridine NDC to their finished compounded human drug products, they may choose to do so.

click here to find a list of Cedazuridine suppliers with NDC on PharmaCompass.

Cedazuridine GMP

Cedazuridine Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.

GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).

PharmaCompass offers a list of Cedazuridine GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Cedazuridine GMP manufacturer or Cedazuridine GMP API supplier for your needs.

Cedazuridine CoA

A Cedazuridine CoA (Certificate of Analysis) is a formal document that attests to Cedazuridine's compliance with Cedazuridine specifications and serves as a tool for batch-level quality control.

Cedazuridine CoA mostly includes findings from lab analyses of a specific batch. For each Cedazuridine CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.

Cedazuridine may be tested according to a variety of international standards, such as European Pharmacopoeia (Cedazuridine EP), Cedazuridine JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Cedazuridine USP).

Inform the supplier about your product requirements, specifying if you need a product with particular monograph like EP (Ph. Eur.), USP, JP, BP, or any other quality. In addition, clarify whether you need hydrochloride (HCl), anhydricum, base, micronisatum or a specific level of purity. To find reputable suppliers, utilize the filters and select those certified by GMP, FDA, or any other certification as per your requirement.
For your convenience, we have listed synonyms and CAS numbers to help you find the best supplier. The use of synonyms and CAS numbers can be helpful in identifying potential suppliers, but it is crucial to note that they might not always indicate the exact same product. It is important to confirm the product details with the supplier before making a purchase to ensure that it meets your requirements.
Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty